Advanced

Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.

Hao, Wende; Zhang, Xuhui; Xiu, Bingshui; Yang, Xiqin; Hu, Shuofeng; Liu, Zhiqiang; Duan, Cuimi; Jin, Shujuan; Ying, Xiaomin and Zhao, Yanfeng, et al. (2016) In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Abstract
Breast cancer is the most common cancer in women worldwide, identification of new biomarkers for early diagnosis and detection will improve the clinical outcome of breast cancer patients. In the present study, we determined serum levels of vitronectin (VN) in 93 breast cancer patients, 30 benign breast lesions, 9 precancerous lesions, and 30 healthy individuals by enzyme-linked immunosorbent assays. Serum VN level was significantly higher in patients with stage 0-I primary breast cancer than in healthy individuals, patients with benign breast lesion or precancerous lesions, as well as those with breast cancer of higher stages. Serum VN level was significantly and negatively correlated with tumor size, lymph node status, and clinical stage... (More)
Breast cancer is the most common cancer in women worldwide, identification of new biomarkers for early diagnosis and detection will improve the clinical outcome of breast cancer patients. In the present study, we determined serum levels of vitronectin (VN) in 93 breast cancer patients, 30 benign breast lesions, 9 precancerous lesions, and 30 healthy individuals by enzyme-linked immunosorbent assays. Serum VN level was significantly higher in patients with stage 0-I primary breast cancer than in healthy individuals, patients with benign breast lesion or precancerous lesions, as well as those with breast cancer of higher stages. Serum VN level was significantly and negatively correlated with tumor size, lymph node status, and clinical stage (p < 0.05 in all cases). In addition, VN displayed higher area under curve (AUC) value (0.73, 95 % confidence interval (CI) [0.62-0.84]) than carcinoembryonic antigen (CEA) (0.64, 95 % CI [0.52-0.77]) and cancer antigen 15-3 (CA 15-3) (0.69, 95 % CI [0.58-0.81]) when used to distinguish stage 0-I cancer and normal control. Importantly, the combined use of three biomarkers yielded an improvement in receiver operating characteristic curve with an AUC of 0.83, 95 % CI [0.74-0.92]. Taken together, our current study showed for the first time that serum VN is a promising biomarker for early diagnosis of breast cancer when combined with CEA and CA15-3. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
publisher
Springer
external identifiers
  • PMID:26753956
  • Scopus:84954172198
ISSN
1423-0380
DOI
10.1007/s13277-015-4750-y
language
English
LU publication?
yes
id
dba86878-5578-4fbb-9beb-74785b14b603 (old id 8592371)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26753956?dopt=Abstract
date added to LUP
2016-02-02 21:56:18
date last changed
2016-10-30 04:36:48
@misc{dba86878-5578-4fbb-9beb-74785b14b603,
  abstract     = {Breast cancer is the most common cancer in women worldwide, identification of new biomarkers for early diagnosis and detection will improve the clinical outcome of breast cancer patients. In the present study, we determined serum levels of vitronectin (VN) in 93 breast cancer patients, 30 benign breast lesions, 9 precancerous lesions, and 30 healthy individuals by enzyme-linked immunosorbent assays. Serum VN level was significantly higher in patients with stage 0-I primary breast cancer than in healthy individuals, patients with benign breast lesion or precancerous lesions, as well as those with breast cancer of higher stages. Serum VN level was significantly and negatively correlated with tumor size, lymph node status, and clinical stage (p &lt; 0.05 in all cases). In addition, VN displayed higher area under curve (AUC) value (0.73, 95 % confidence interval (CI) [0.62-0.84]) than carcinoembryonic antigen (CEA) (0.64, 95 % CI [0.52-0.77]) and cancer antigen 15-3 (CA 15-3) (0.69, 95 % CI [0.58-0.81]) when used to distinguish stage 0-I cancer and normal control. Importantly, the combined use of three biomarkers yielded an improvement in receiver operating characteristic curve with an AUC of 0.83, 95 % CI [0.74-0.92]. Taken together, our current study showed for the first time that serum VN is a promising biomarker for early diagnosis of breast cancer when combined with CEA and CA15-3.},
  author       = {Hao, Wende and Zhang, Xuhui and Xiu, Bingshui and Yang, Xiqin and Hu, Shuofeng and Liu, Zhiqiang and Duan, Cuimi and Jin, Shujuan and Ying, Xiaomin and Zhao, Yanfeng and Han, Xiaowei and Hao, Xiaopeng and Fan, Yawen and Johnson, Heather and Meng, Di and Persson, Jenny L and Zhang, Heqiu and Feng, XiaoYan and Huang, Yan},
  issn         = {1423-0380},
  language     = {eng},
  month        = {01},
  publisher    = {ARRAY(0x9b614f0)},
  series       = {Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine},
  title        = {Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.},
  url          = {http://dx.doi.org/10.1007/s13277-015-4750-y},
  year         = {2016},
}